Skip to main content

UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC

Position in HALO — Halozyme Therapeutics, Inc.

CIK 861177 NEW YORK, NY

Position in HALO

as of Mar 31, 2026 · filed May 13, 2026
Position Value
$34,126,640
-$15,242,078 QoQ
Shares Held
528,031
-28.0% QoQ
Ownership
0.445%
of shares outstanding
% of Portfolio
0.01%
of 13F equity value
Holder Rank
not a current holder
Holding Since
Mar 2020
25 quarters on record
Voting authority Sole 58.47895294026297.ToString("F0")% Shared 0.ToString("F0")% None 41.52104705973702.ToString("F0")%

Common Shares in HALO Over Time

Shares Held

Position Value (USD)

Position in Biotechnology

Healthcare · as of Mar 31, 2026

UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC holds $4,287,037,771 across 211 Biotechnology names. HALO ranks #21 (0.8% of the industry book) .

# Ticker Company Shares Value (USD) Open

All Filings in HALO

Export CSV
25 filing rows on record
Report Date Value (USD) Shares
2026-03-31 $34,126,640 528,031
2025-12-31 $49,368,718 733,562
2025-09-30 $23,979,754 326,967
2025-06-30 $25,819,809 496,344
2025-03-31 $26,561,674 416,262
2024-12-31 $18,639,919 389,875
2024-09-30 $22,771,957 397,833
2024-06-30 $22,620,770 432,024
2024-03-31 $6,547,607 160,954
2023-12-31 $5,957,210 161,180
2023-09-30 $6,017,911 157,537
2023-06-30 $12,069,307 334,608
2023-03-31 $12,778,677 334,608
2022-12-31 $29,501,453 518,479
2022-09-30 $20,558,860 519,951
2022-06-30 $7,782,016 176,864
2022-03-31 $6,678,501 167,465
2021-12-31 $6,066,399 150,868
2021-09-30 $6,009,980 147,738
2021-06-30 $7,051,943 155,295
2021-03-31 $6,299,441 151,102
2020-12-31 $6,584,897 154,177
2020-09-30 $3,710,733 141,200
2020-06-30 $3,897,957 145,392
2020-03-31 $15,708,722 873,192